Yousif Capital Management LLC Has $812,000 Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Yousif Capital Management LLC lowered its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 4.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 58,081 shares of the biopharmaceutical company’s stock after selling 2,717 shares during the period. Yousif Capital Management LLC’s holdings in Dynavax Technologies were worth $812,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in the business. BluePath Capital Management LLC acquired a new stake in shares of Dynavax Technologies in the third quarter worth $33,000. DekaBank Deutsche Girozentrale acquired a new stake in Dynavax Technologies in the 3rd quarter worth $33,000. Advisor Resource Council bought a new position in shares of Dynavax Technologies during the 4th quarter worth about $144,000. Rathbones Group PLC acquired a new position in shares of Dynavax Technologies during the third quarter valued at about $158,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Dynavax Technologies in the fourth quarter valued at about $209,000. 96.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on DVAX. The Goldman Sachs Group started coverage on Dynavax Technologies in a report on Thursday, February 1st. They issued a “neutral” rating and a $20.00 price target for the company. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 23rd. Finally, StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Friday, April 26th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Dynavax Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Dynavax Technologies Trading Up 0.2 %

DVAX stock opened at $11.74 on Friday. Dynavax Technologies Co. has a 1-year low of $10.57 and a 1-year high of $15.15. The company has a current ratio of 13.81, a quick ratio of 12.96 and a debt-to-equity ratio of 0.41. The business’s 50 day moving average is $12.14 and its 200-day moving average is $13.08. The firm has a market cap of $1.54 billion, a P/E ratio of -195.63 and a beta of 1.30.

Insider Activity at Dynavax Technologies

In other Dynavax Technologies news, CAO Justin Burgess sold 20,526 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $12.78, for a total transaction of $262,322.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.98% of the stock is owned by insiders.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.